Glaucoma News and Research

Latest Glaucoma News and Research

Sleep Science's new OSA treatment to be presented in WHO Compendium of Innovative Technologies

Sleep Science Partners' mandibular repositioning treatment for obstructive sleep apnea has been accepted for inclusion in the 2013 World Health Organization Compendium of Innovative Technologies to be published this November.

6 Nov 2013

NTU establishes new $60 million research institute in Nanomedicine

Nanyang Technological University is giving the development of nanotechnology a big boost, by establishing a new $60 million research institute in Nanomedicine, which focuses on the medical application of nanotechnology. An emerging field in drugs, nanomedicine are made up of tiny nano-sized particles thousands of times smaller than a grain of sand.

5 Nov 2013

Oligomeric proanthocyanidin has protective effect on retinal ganglion cells, shows study

The death of retinal ganglion cells is a hallmark of many optic neurodegenerative diseases such as glaucoma and retinopathy. Oxidative stress is one of the major reasons to cause the cell death.

4 Nov 2013

Eliza's Star multi-modal programs address gaps in healthcare

Eliza Corporation ("Eliza"), the pioneer and recognized leader in Health Engagement Management, today announced "Star 2014", a proactive member communication solutions suite that addresses key areas of the Centers for Medicare & Medicaid Services (CMS) Star programs.

30 Oct 2013

Once-daily prescription medicine for COPD now available throughout the U.S.

GlaxoSmithKline plc and Theravance, Inc. today announced that BREO ELLIPTA, a once-daily prescription medicine for chronic obstructive pulmonary disease, is now available to pharmacies throughout the U.S.

30 Oct 2013

$Adalimumab may be viable treatment option for patients with refractory pediatric uveitis$

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

A new study published in the current issue of the Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) suggests that the biologic agent adalimumab may be a viable treatment option for patients with steroid-resistant refractory pediatric uveitis.

22 Oct 2013

pSivida reports that Alimera Sciences gets FDA Complete Response Letter for ILUVIEN NDA

pSivida Corp., a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that its licensee Alimera Sciences, Inc. has received a Complete Response Letter for the New Drug Application for ILUVIEN from the U.S. Food and Drug Administration.

18 Oct 2013

ADAGES III study receives NIH grant to elucidate genetics of glaucoma in African descents

A study led by Robert N. Weinreb, chairman and Distinguished Professor of Ophthalmology at the University of California, San Diego School of Medicine, has received a $6.4 million, 5-year grant from the National Eye Institute, part of the National Institutes of Health, to elucidate the genetics of glaucoma in persons of African descent.

12 Oct 2013

Data analyses from Brisdelle Phase 3 pivotal trials to be showcased at NAMS' meeting

Noven Pharmaceuticals, Inc., today announced that 11 presentations, featuring data analyses from its Phase 3 pivotal trials that supported the recent U.S. Food and Drug Administration approval of Brisdelle (paroxetine capsules, 7.5 mg/day) for the treatment of moderate to severe vasomotor symptoms associated with menopause, will be showcased at the 2013 Annual Meeting of The North American Menopause Society in Dallas on Oct. 9-10.

2 Oct 2013

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

...

2 Oct 2013

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

...

1 Oct 2013

Sun Pharma, Intrexon partner to develop controllable gene-based therapies for ocular diseases

Sun Pharmaceutical Industries Ltd., an international specialty pharmaceutical company focused on chronic diseases, through its subsidiary, and Intrexon Corporation, a leader in synthetic biology, today announced the formation of a joint venture to develop controllable gene-based therapies for the treatment of ocular diseases that cause partial or total blindness in millions of people worldwide.

1 Oct 2013

Optic flow enables perception despite blur image

Blurred images that are unidentifiable as still pictures become understandable once the images are set in motion. That's because of a phenomenon called "optic flow"—which may be especially relevant as a source of visual information in people with low vision, reports a study 'With an Eye to Low Vision: Optic Flow Enables Perception Despite Image Blur' in the October issue of Optometry and Vision Science official journal of the American Academy of Optometry.

27 Sep 2013

IRIDEX's MicroPulse Laser Therapy to be featured at EURETINA and ESCRS conferences

IRIDEX today announced a number of key international conferences and workshops that will feature its proprietary MicroPulse Laser Therapy for the treatment of diabetes and glaucoma related disorders.

26 Sep 2013

New laser provides better treatment for eye diseases in diabetes patients

A new laser is helping experts at the Truhlsen Eye Institute at the University of Nebraska Medical Center provide better treatment for eye diseases. This advanced laser can prevent blindness for some patients with serious conditions.

24 Sep 2013

Longer looks: Phenomenal growth of the Cleveland Clinic prompts hopes for the city; the bittersweet decision to donate organs

Delos M. "Toby" Cosgrove arrived at the Cleveland Clinic in 1975 as an "incredibly poor" 34-year-old dreaming of a life as a cardiac surgeon. … As the years passed he became well-known for pioneering the replacement of heart valves, eventually assuming the chair of the department of cardiothoracic surgery.

From Medtronic 5 Sep 2013

Prevalence for major eye disease is higher in people with common sleep disorder

Researchers in Taiwan have discovered that people with sleep apnea are far more likely to develop glaucoma compared to those without the sleep condition. The results of this study, which is the first to calculate the risk of the disease among people with the sleep disorder following diagnosis, is published in this month's edition of Ophthalmology, the journal of the American Academy of Ophthalmology.

8 Aug 2013

Forest Laboratories, Pierre Fabre Laboratories announce that FETZIMA gets FDA approval for MDD

Forest Laboratories, Inc. and Pierre Fabre Laboratories announced today that FETZIMA (levomilnacipran extended-release capsules), a once-daily serotonin and norepinephrine reuptake inhibitor, discovered by Pierre Fabre Laboratories and co-developed by Forest Laboratories, Inc. was approved by the U.S. Food and Drug Administration for the treatment of Major Depressive Disorder in adults.

26 Jul 2013

Research roundup: Eye care disparities; more complications for Medicaid patients after spine surgery; the cost to states opting against Medicaid expansion

After analyzing 2003-2004 data of patients who underwent spinal surgery at two medical institutions, they found that Medicaid beneficiaries were at much higher risk of experiencing any type of complication than patients who are privately insured. "The results of our study further support the growing body of literature that Medicaid patients have higher rates of complications," the authors write. When evaluating patients and considering the likelihood of complications, "Medicaid status should be considered as well," they concluded (Hacquebord et al., 7/15).

20 Jul 2013

Bausch + Lomb obtains option to license MIM-D3 for treatment of dry eye syndrome

Bausch + Lomb, the global eye health company, and Mimetogen Pharmaceuticals Inc. today announced that Bausch + Lomb has acquired an option to license an investigational compound currently in Phase 2 development for the treatment of dry eye syndrome, a condition that affects millions of people worldwide.

19 Jul 2013

Glaucoma News and Research

Latest Glaucoma News and Research

Sleep Science's new OSA treatment to be presented in WHO Compendium of Innovative Technologies

NTU establishes new $60 million research institute in Nanomedicine

Oligomeric proanthocyanidin has protective effect on retinal ganglion cells, shows study

Eliza's Star multi-modal programs address gaps in healthcare

Once-daily prescription medicine for COPD now available throughout the U.S.

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

pSivida reports that Alimera Sciences gets FDA Complete Response Letter for ILUVIEN NDA

ADAGES III study receives NIH grant to elucidate genetics of glaucoma in African descents

Data analyses from Brisdelle Phase 3 pivotal trials to be showcased at NAMS' meeting

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

Sun Pharma, Intrexon partner to develop controllable gene-based therapies for ocular diseases

Optic flow enables perception despite blur image

IRIDEX's MicroPulse Laser Therapy to be featured at EURETINA and ESCRS conferences

New laser provides better treatment for eye diseases in diabetes patients

Longer looks: Phenomenal growth of the Cleveland Clinic prompts hopes for the city; the bittersweet decision to donate organs

Prevalence for major eye disease is higher in people with common sleep disorder

Forest Laboratories, Pierre Fabre Laboratories announce that FETZIMA gets FDA approval for MDD

Research roundup: Eye care disparities; more complications for Medicaid patients after spine surgery; the cost to states opting against Medicaid expansion

Bausch + Lomb obtains option to license MIM-D3 for treatment of dry eye syndrome

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Glaucoma News and Research

Latest Glaucoma News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in